DREAMM9
A Phase 1 Study of Belantamab Mafodotin Plus Standard of Care in Newly Diagnosed Multiple Myeloma
Arms / Cohorts
Cohort 1:Belantamab Mafodotin + Bortezomib + Lenalidomide + Dexamethasone
Accepting patients
Cohort 2:Belantamab Mafodotin + Bortezomib + Lenalidomide + Dexamethasone
Accepting patients
Cohort 3:Belantamab Mafodotin + Bortezomib + Lenalidomide + Dexamethasone
Accepting patients
Cohort 4:Belantamab Mafodotin + Bortezomib + Lenalidomide + Dexamethasone
Accepting patients
Cohort 5:Belantamab Mafodotin + Bortezomib + Lenalidomide + Dexamethasone
Accepting patients
Cohort 6:Belantamab Mafodotin + Bortezomib + Lenalidomide + Dexamethasone
Accepting patients
Cohort 7:Belantamab Mafodotin + Bortezomib + Lenalidomide + Dexamethasone
Accepting patients
Cohort 8a:Belantamab Mafodotin + Bortezomib + Lenalidomide + Dexamethasone
Accepting patients
Cohort 8b:Belantamab Mafodotin + Bortezomib + Lenalidomide + Dexamethasone
Accepting patients
Cohort 8c:Belantamab Mafodotin + Bortezomib + Lenalidomide + Dexamethasone
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.